Two Small Biotech Companies May Revolutionize Cancer Treatment with New Medicines

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) and its T-cell immunotherapy Amtagvi are driving the biotech firm's share price growth. Amtagvi has been approved in the US for melanoma and has potential for $1 billion in sales at its peak. The drug also received Fast Track Designation for non-small cell lung cancer and may be effective against multiple cancers. Despite manufacturing challenges and high risks, analysts expect significant gains with a consensus price target of $8.88.